Document is current
Any future updates will be listed below
-
Authors
Coleman, Kate E.
Shin, Dong-Woo https://orcid.org/0009-0003-5909-972X
Goehring, Liana
Szeitz, Beata
Fenyö, David
Rothenberg, Eli https://orcid.org/0000-0002-1382-1380
Poirier, John T. https://orcid.org/0000-0001-9795-5644
Huang, Tony T. https://orcid.org/0000-0001-9291-5002
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA288368)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM139610)
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (ES031658)
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 28 October 2025
First Online: 10 December 2025
Competing interests
: T.T.H. and J.T.P. have applied for a method of use patent related to targeting RFWD3 and PRIMPOL in cells that lack SLFN11. The remaining authors declare no competing interests.
